Phase II trial of pegylated interferon and thalidomide in malignant metastatic melanoma-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Phase II trial of pegylated interferon and thalidomide in malignant metastatic melanoma

Published:2007-11 Issue:10 Volume:18 Page:1221-1226
ISSN:0959-4973
Container-title:Anti-Cancer Drugs
language:en
Short-container-title:

Author:

Vaishampayan Ulka N.,Heilbrun Lance K.,Marsack Cynthia,Smith Daryn W.,Flaherty Lawrence E.

Publisher

Ovid Technologies (Wolters Kluwer Health)

Subject

Cancer Research,Pharmacology (medical),Pharmacology,Oncology

Reference30 articles.

1. Treatment of metastatic malignant melanoma;Atallah;Curr Treat Options Oncol,2005

2. Bcl-2 antisense (oblimersen sodium) plus dacarbazine in patients with advanced melanoma: the Oblimersen Melanoma Study Group;Bedikian;J Clin Oncol,2006

3. Interferon alfa-2b adjuvant therapy of high-risk resected cutaneous melanoma: the Eastern Cooperative Oncology Group Trial EST 1684;Kirkwood;J Clin Oncol,1996

4. Sequential biochemotherapy versus chemotherapy for metastatic melanoma: results from a phase III randomized trial;Eton;J Clin Oncol,2002

5. Antitumor effects of interferon;Gresser;Acta Oncol,1989

Cited by 9 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. VEGF/VEGFR axis and its signaling in melanoma: Current knowledge toward therapeutic targeting agents and future perspectives;Life Sciences;2024-05

2. Overcoming Resistance in Relapsed Anaplastic Large-Cell Lymphoma, ALK-Positive (Literature Review and Clinical Experience);Clinical oncohematology;2019

3. Advanced targeted therapies in cancer: Drug nanocarriers, the future of chemotherapy;European Journal of Pharmaceutics and Biopharmaceutics;2015-06

4. ECOG Phase II Trial of Graded-Dose Peginterferon α-2b in Patients with Metastatic Melanoma Overexpressing Basic Fibroblast Growth Factor (E2602);Clinical Cancer Research;2013-10-11

5. The Enhancement of Radiosensitivity in Human Esophageal Carcinoma Cells by Thalidomide and Its Potential Mechanism;Cancer Biotherapy and Radiopharmaceuticals;2011-04

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3